CD40-binding activating antibodies
Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells. Several such monoclonal antibodies are provided, and cell lines producing them have been deposited at the American Type Culture Collection.
1. An anti-CD40 monoclonal antibody, wherein said anti-CD40 antibody is produced by a hybridoma selected from the group consisting of hybridomas deposited with American Type Culture Collection (ATCC) as deposit designation PTA-2993, PTA-2994, PTA-2995, PTA-2996, PTA-2997, PTA-2998 and PTA-2999.
2. A hybridoma selected from the group consisting of hybridomas deposited with American Type Culture Collection (ATCC) as deposit designation PTA-2993, PTA-2994, PTA-2995, PTA-2996, PTA-2997, PTA-2998 and PTA-2999.
3. A composition comprising a combination of two or more monoclonal antibodies according to claim 1 .
4. A cell line that produces the anti-CD40 monoclonal antibody of claim 1 .
5. An anti-CD40 monoclonal antibody that is a chimeric antibody, humanized antibody, single chain antibody or CD40-binding fragment thereof, of the antibody according to claim 1 .
6. The anti-CD40 monoclonal antibody according to claim 5 from which the potential human T cell epitopes have been eliminated.
7. The CD40-binding fragment according to claim 5 , which is an Fab, F(ab′) 2 , Fv, or single chain Fv fragment.
8. A composition comprising a combination of two or more chimeric antibodies, humanized antibodies, single chain antibodies or CD40-binding fragments thereof according to claim 5 .
9. A composition comprising a combination of one or more anti-CD40 monoclonal antibodies according to claim l with one or more chimeric antibodies, humanized antibodies, single chain antibodies or CD40-binding fragments thereof according to claim 5 .
10. A cell line that produces the chimeric antibody, humanized antibody, single chain antibody or CD40-binding fragment thereof according to claim 5 .